Centene ribociclib (Kisqali) Coverage Update

Coverage Criteria for Ribociclib (Kisqali) and Kisqali Femara

Initial Approval — Breast Cancer

Covered when ALL of the following are met:

Initial Approval Criteria for Breast Cancer: 1) Diagnosis of breast cancer; 2) Prescription is by or in consultation with an oncologist; 3) Patient is >= 18 years of age; 4) Disease is hormone receptor (HR)-positive (ER and/or PR positive) AND HER2-negative; 5) Disease is either advanced/recurrent/metastatic OR Stage II/III early breast cancer at high risk of recurrence; 6) If request is for Kisqali, therapy is prescribed in combination with an aromatase inhibitor (e.g., letrozole, anastrozole, exemestane) as initial endocrine-based therapy or adjuvant therapy, or with fulvestrant where indicated; if request is for Kisqali Femara, prescribed as initial endocrine-based therapy or as adjuvant therapy; 7) If the patient is premenopausal or perimenopausal female, patient has been treated with ovarian ablation or is receiving ovarian suppression; 8) If male and receiving an aromatase inhibitor, therapy is prescribed with an agent that suppresses testicular steroidogenesis (e.g., GnRH agonist); 9) Member has not previously experienced disease progression on a CDK4/6 inhibitor; 10) Requested agent is not prescribed concurrently with another CDK4/6 inhibitor; 11) For brand Kisqali requests, member must use generic ribociclib if available unless contraindicated or clinically significant adverse effects are experienced; 12) Dose does not exceed the specified regimen limits for the requested indication (see dosing criteria).

Supported by chunks 5 and 6.

Dosing Constraints (initial and continued)

Dose limits by indication and product (initial and continued):

Allowed dosing options: Advanced/recurrent/metastatic breast cancer: Kisqali (ribociclib) dosing up to 600 mg PO once daily for 21 consecutive days followed by 7 days off per 28-day cycle; when provided as ribociclib/letrozole (Kisqali Femara) combine with letrozole 2.5 mg PO once daily for a 28-day cycle. Early (adjuvant) breast cancer: Kisqali dosing up to 400 mg PO once daily for 21 consecutive days followed by 7 days off per 28-day cycle; when used as Kisqali Femara combine with letrozole 2.5 mg PO once daily.Kisqali: 600 mg/day (advanced) or 400 mg/day (early); Letrozole: 2.5 mg/day

Prescribed regimen must be FDA‑approved or recommended by NCCN; off‑label doses require supporting literature and prescriber evidence (chunk 9, 13).

Dose change and reduction rules: For requests to increase dose during therapy, new dose must not exceed indication-specific maximums (600 mg/day for advanced/metastatic; 400 mg/day for early breast cancer). If dose reduction to 200 mg/day is required, therapy should be discontinued.max=600 mg/day (advanced); max=400 mg/day (early); discontinue if reduced to 200 mg/day

Dose limits are enforced per 28-day cycle; see continued therapy dosing language for dose-increase rules (chunks 12, 13, 21, 22).

Initial Approval — Endometrial Carcinoma (off-label)

Covered when ALL of the following are met:

Endometrial Carcinoma (off-label) Initial Approval: 1) Diagnosis of endometrial carcinoma; 2) Prescription by or in consultation with an oncologist; 3) Patient is >= 18 years of age; 4) Presence of ER-positive tumors; 5) If request is for Kisqali, therapy is prescribed in combination with letrozole; 6) Agent is not prescribed concurrently with another CDK4/6 inhibitor; 7) For brand Kisqali requests, member must use generic ribociclib if available unless contraindicated or clinically significant adverse effects are experienced; 8) Dose is within FDA maximum limits for any FDA‑approved indication or supported by practice guidelines/peer‑reviewed literature for this off‑label use (prescriber must submit supporting evidence).

Approval duration for this off‑label indication: 6 months (chunk 9).

Continued Therapy

Criteria for renewal/continuation — member must meet ALL of the following:

Continued Therapy Criteria: 1) Member is currently receiving the medication via the Centene benefit OR documentation supports that the member has received Kisqali or Kisqali Femara for at least 21 days; 2) Member is responding positively to therapy as documented by the prescriber; 3) Requested agent is not prescribed concurrently with another CDK4/6 inhibitor; 4) For brand Kisqali requests, member must use generic ribociclib if available unless contraindicated or clinically significant adverse effects are experienced; 5) Any requested dose increase must not exceed the indication-specific maximums (600 mg/day advanced; 400 mg/day early) or must be supported by practice guidelines/peer-reviewed literature submitted by the prescriber.Minimum 21 days on therapy before continuation consideration

Approval durations vary by line of business (see chunk 14).

Coverage highlights

Coverage considerations and quick highlights:

Early breast cancer dosing and duration: Ribociclib dosing for early breast cancer: 400 mg PO once daily for 21 days followed by 7 days off; continue treatment for 3 years or until disease recurrence or unacceptable toxicity. If dose must be reduced to 200 mg/day, therapy should be discontinued.duration = 3 years

Maximum daily dose for early breast cancer = 400 mg/day (chunks 21, 22).

Advanced/metastatic dosing: Ribociclib dosing for advanced/metastatic breast cancer: 600 mg PO once daily for 21 days followed by 7 days off; combine with appropriate endocrine therapy per indication (e.g., letrozole or fulvestrant).max = 600 mg/day

Combination with fulvestrant expanded to include perimenopausal females when ovarian ablation/suppression is provided (chunk 26).

Safety and contraindications: Known hypersensitivity to letrozole or any excipients of Femara is a contraindication to Kisqali Femara; NCCN no longer supports combination with tamoxifen due to QT prolongation concerns.

Non‑FDA approved indications that are not specifically addressed in this policy are not covered unless the prescriber supplies sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies: CP CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), or CP PMN.53 (Medicaid).

The National Comprehensive Cancer Network (NCCN) no longer supports combining ribociclib (Kisqali) with tamoxifen; this combination was removed from the breast cancer guidelines and is discouraged because of QT‑interval prolongation risk. Additionally, Kisqali Femara is contraindicated in patients with a known hypersensitivity to letrozole or any excipients of Femara.

Requests for uses not on the formulary or PDL must follow the referenced non‑formulary and off‑label policies for the member's line of business. For formulary/PDL situations or for drugs not on the formulary, providers should refer to the policy references listed (e.g., CP.CPA.190, HIM.PA.103, CP PMN.16) and the off‑label use policies (CP CPA.09, HIM.PA.154, CP.PMN.53) when applicable.

There are no data to support retreatment with a different CDK4/6 inhibitor regimen after disease progression on a prior CDK4/6 inhibitor; sequential or concurrent use of another CDK4/6 inhibitor in this setting is not supported and may be considered not medically necessary.

Initial Therapy Requirements

Initial therapy

Initial therapy — top-level requirements (must meet ALL):

Initial therapy top-level requirements: 1) Diagnosis of breast cancer; 2) Prescribed by or in consultation with an oncologist; 3) Age >= 18 years; 4) HR-positive (ER and/or PR) AND HER2-negative disease; 5) Disease stage: advanced/recurrent/metastatic OR Stage II/III early breast cancer at high risk of recurrence; 6) Appropriate combination endocrine partner: for Kisqali an aromatase inhibitor or fulvestrant as applicable; for Kisqali Femara as initial endocrine-based or adjuvant therapy; 7) Premenopausal/perimenopausal females require ovarian ablation or suppression; 8) No prior progression on a CDK4/6 inhibitor; 9) No concurrent CDK4/6 inhibitor use; 10) Brand-to-generic redirection applies for Kisqali where available; 11) Requested dose must be within stated limits for the indication.

Aligned with initial approval criteria (chunks 5, 6).

Initial therapy dosing rules

Initial therapy dosing rules and limits:

Initial dosing — advanced/metastatic: Ribociclib (Kisqali) 600 mg PO once daily for 21 consecutive days followed by 7 days off per 28-day cycle when used for advanced or metastatic disease; when provided as Kisqali Femara include letrozole 2.5 mg PO once daily for each 28-day cycle.

Criteria for Continued Therapy

Continued therapy

Continued therapy — operational renewal requirements (must meet ALL):

Continued therapy operational requirements: 1) Member is currently receiving medication via Centene benefit OR documentation supports the member has received Kisqali/Kisqali Femara for at least 21 days prior to the request; 2) Member is demonstrating clinical benefit and responding to therapy as documented by the prescriber; 3) Requested agent is not being used concurrently with another CDK4/6 inhibitor; 4) Brand-to-generic redirection applies for Kisqali where available; 5) Any dose increases must adhere to indication-specific maximums or be supported by practice guidelines/peer-reviewed literature.Minimum 21 days on therapy before continuation consideration

See continued therapy section for dose-increase rules (chunks 11, 12).

Continuation therapy considerations

Continuation therapy considerations and nuances:

Response documentation and duration:

Provider Actions and Authorization Requirements

Prior Authorization

Prior Authorization Required

Prior Authorization Required: Prior authorization is required. The provider must submit clinical documentation (office/chart notes, labs, imaging, pathology, treatment history) demonstrating the member meets the approval criteria, including diagnosis, oncologist involvement, age, disease stage (advanced/recurrent/metastatic versus early high‑risk), hormone receptor and HER2 status, and prior CDK4/6 inhibitor exposure. Failure to submit required supporting documentation may result in denial.

Submit office notes, relevant labs and diagnostic reports, and medication history with the prior authorization request
Clearly document whether the indication is advanced/recurrent/metastatic or early breast cancer (stage II/III high risk)

Billing Rule

Dose Limits and Dosing Regimens Enforced

Dose Limit Enforcement: Dose limits are enforced per 28‑day cycle. Prescribing must adhere to maximum daily doses and dosing schedules for the indicated setting.

Product Availability and Coding

Product availabilityNDC

200 mg

Ribociclib tablet strength available

Maximum daily dose

Advanced / metastatic breast cancerMaximum daily dose: 600 mg/day (600 mg PO QD for 21 days followed by 7 days off)

Early (adjuvant) high‑risk breast cancerMaximum daily dose: 400 mg/day (400 mg PO QD for 21 days followed by 7 days off); continue treatment for 3 years or until recurrence or unacceptable toxicity

Kisqali Femara (ribociclib/letrozole) — advancedKisqali component maximum: 600 mg/day; letrozole 2.5 mg/day

Kisqali Femara — earlyKisqali component maximum: 400 mg/day; letrozole 2.5 mg/day

Step Therapy and Prior Failures

Step	Requirement	Notes
1	For brand Kisqali requests, member must use generic ribociclib if available unless contraindicated or clinically significant adverse effects are experienced.	Applies at initial and continued therapy; prescriber should document contraindication or intolerance to generic product when brand requested.

Step	Prior-failure check	Action if prior CDK4/6 failure documented
1	Confirm member has not previously experienced disease progression on a CDK4/6 inhibitor therapy (e.g., abemaciclib [Verzenio], palbociclib [Ibrance], or others).	If prior progression on a CDK4/6 inhibitor is documented, request is not supported for retreatment or sequential CDK4/6 use per policy; denial or alternative therapy considerations apply.

Quantity Limits

Ribociclib quantity limits

Quantity limit approachAs needed to match dosing regimens up to the maximum daily doses described (tablet strength: 200 mg available)

Advanced/metastatic regimenAllow quantity to cover Kisqali 600 mg/day (three 200 mg tablets) for 21 days per 28-day cycle

Early breast cancer regimenAllow quantity to cover Kisqali 400 mg/day (two 200 mg tablets) for 21 days per 28-day cycle and up to 3 years of treatment per authorization rules

Site of Care and Administration

Note

Site of care — oral therapy; no location restriction

Kisqali and Kisqali Femara are orally administered; no specific site-of-care restriction is specified in this policy extract.

Administration is appropriate in the home setting as an oral therapy.

Background

Ribociclib is a selective CDK4/6 inhibitor indicated as part of endocrine‑based therapy for hormone receptor–positive, HER2‑negative breast cancer. It is administered orally in 21 days on / 7 days off cycles; typical dosing is 600 mg daily for advanced/metastatic disease and 400 mg daily for adjuvant treatment of early high‑risk disease. In early breast cancer, treatment duration is commonly 3 years or until disease recurrence or unacceptable toxicity. When co‑administered as Kisqali Femara, ribociclib is combined with letrozole (an aromatase inhibitor).

Definitions

CDK — definition

CDKCyclin-dependent kinase

ContextEnzyme family involved in cell-cycle regulation; targeted class includes CDK4/6 inhibitors such as ribociclib

HR — definition

HRHormone receptor

ContextRefers to receptors for sex hormones (e.g., estrogen and progesterone) used to characterize breast cancer biology

ER — definition

OpenPayer

Ribociclib (Kisqali), Ribociclib/Letrozole (Kisqali Femara) coverage criteria